Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD [Phase 4]
Open-label Phase 4 study evaluating SPN-812 (viloxazine) in combination with psychostimulants for children and adolescents with Attention-De…
-
CLINICAL_TRIALS research · 2024-04-25Clinical Trial Update: Assessing the Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Undiagnosed Young Adults:A Cross Sectional Study
This completed cross-sectional clinical trial evaluated the prevalence of ADHD symptoms among undiagnosed young adults.
-
FDA approval · 2024-04-18FDA Approved: METHAMPHETAMINE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for methamphetamine hydrochloride (Hikma Pharmaceuticals USA Inc.).
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa [Phase 2]
Phase 2 trial evaluating droxidopa with carbidopa for adults with ADHD; study completed with results posted.
-
FDA approval · 2024-04-11FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Dr.Reddys Laboratories Inc)
FDA approved a supplemental application for methylphenidate hydrochloride from Dr. Reddy's Laboratories Inc, updating the approval for the g…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-04-11Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD [Phase 3]
A Phase 3 study evaluating oral AK0901 for efficacy, safety, and tolerability in children with ADHD is ongoing, with status currently unknow…
-
FDA approval · 2024-04-10FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Northstar Rx LLC)
The FDA approved a supplemental application for methylphenidate hydrochloride from Northstar Rx LLC, authorizing the generic product. Methyl…
-
FDA approval · 2024-04-01FDA Approved: METHYLPHENIDATE HYDROCHLORIDE (LA) — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA approved a supplemental application for methylphenidate hydrochloride (LA) from Dr. Reddy's Laboratories Inc.
-
FDA approval · 2024-04-01FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals,Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for methylphenidate hydrochloride.
-
FDA approval · 2024-04-01FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Elite Laboratories, Inc.)
The FDA approved Elite Laboratories, Inc.'s supplemental application for a fixed combination of amphetamine salts (dextroamphetamine sacchar…
-
FDA approval · 2024-04-01FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Neolpharma, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride from Neolpharma, Inc. under ANDA208737, granting approval for this…
-
FDA approval · 2024-04-01FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE EXTENDED-RELEASE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's supplemental application for a generic mixed amphetamine salts extended-release product (dextroamphetamine…
-
FDA approval · 2024-03-28FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for a generic product containing four amphetamine salt components, manufactured by Sun Pharmaceu…
-
FDA approval · 2024-03-28FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved ANI Pharmaceuticals' supplemental ANDA for a generic combination of amphetamine/dextroamphetamine salts used to treat attention…
-
FDA approval · 2024-03-28FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals,Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for methylphenidate hydrochloride, a generic stimulant product, enabling it…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: A+ Treatment/Feasibility of Adapted ESDM-informed Caregiver Coaching Delivered Remotely for Children With ASD (Autism Spectrum Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) [NA]
Completed clinical trial evaluating feasibility of adapted ESDM-informed caregiver coaching delivered remotely for children with autism spec…
-
CLINICAL_TRIALS trial_result · 2024-03-19Clinical Trial Update: Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD [Phase 1]
Phase 1 clinical trial evaluating vitamin D as a therapeutic adjunct in stimulant treatment for ADHD completed with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2) [Phase 3]
Phase 3 clinical trial CHIME 2 evaluating treatment for impulsive aggression in subjects with ADHD, completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: Adapting a Web-Based Professional Development for Mexican School Mental Health Providers Delivering Evidence-Based Intervention for ADHD and ODD [NA]
A completed clinical trial evaluating a web-based professional development program for Mexican school mental health providers delivering evi…
-
CLINICAL_TRIALS withdrawal · 2024-03-15Clinical Trial Update: Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD [Phase 4]
Phase 4 clinical trial investigating multimodal brain imaging of methylphenidate in children and adolescents with ADHD has been withdrawn.
-
FDA approval · 2024-03-12FDA Approved: COTEMPLA XR-ODT — Supplemental Application (Neos Therapeutics Brands, LLC)
The FDA approved a supplemental NDA for Cotempla XR-ODT, a methylphenidate product from Neos Therapeutics Brands, LLC.
-
FDA label_change · 2024-03-12FDA Approved: AMPHETAMINE EXTENDED-RELEASE — Supplemental Application (Neos Therapeutics, LP)
The FDA approved a supplemental application for AMPHETAMINE EXTENDED-RELEASE by Neos Therapeutics, LP.
-
FDA approval · 2024-03-08FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (KVK-Tech, Inc.)
FDA approved a supplemental application for dextroamphetamine sulfate from KVK-Tech, Inc., making the generic product available via an appro…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults [Phase 2, Phase 3]
A controlled study of solriamfetol for ADHD in adults across Phase 2 and Phase 3 has completed with results posted.
-
FDA approval · 2024-02-28FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride from Sun Pharmaceutical Industries, expanding the approval status …